Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq) in HIV-1- Infected Patients

Trial Profile

Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq) in HIV-1- Infected Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Abacavir/dolutegravir/lamivudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MONCAY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
    • 20 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top